Tacrine (Cognex)

Subscribe to Selected New Research on Tacrine

508 relevant articles (55 outcomes, 98 trials/studies) found for this Drug

Description: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.

Also Known As:

Cognex; 1,2,3,4-Tetrahydro-9-acridinamine; 1,2,3,4-Tetrahydroaminoacridine; 9-Amino-1,2,3,4-Tetrahydroacridine; Horizon Brand of Tacrine Hydrochloride; OTL Pharm Brand of Tacrine Hydrochloride; Parke Davis Brand of Tacrine Hydrochloride; Romotal; THA; Tacrine Hydrochloride; Tenakrin; Woods Brand of Tacrine Hydrochloride; Tetrahydroaminoacridine; 9-Acridinamine, 1,2,3,4-tetrahydro-

Relationship Network

Drug Context: Research Results

Experts

1.	Szeto, S: 3 articles (01/2007 - 01/2000)
2.	Qizilbash, N: 3 articles (01/2007 - 01/2000)
3.	Lewington, S: 3 articles (01/2007 - 01/2000)
4.	Birks, J: 3 articles (01/2007 - 01/2000)
5.	Lopez Arrieta, J: 2 articles (01/2007 - 01/2000)
6.	Blennow, K: 2 articles (02/2003 - 01/2001)
7.	Mohr, E: 2 articles (05/2002 - 01/2002)
8.	Mahoney, C: 2 articles (05/2002 - 01/2002)
9.	Ilivitsky, V: 2 articles (05/2002 - 01/2002)
10.	Engeland, C: 2 articles (05/2002 - 01/2002)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 02/01/1998 - "CSF concentrations ranged from not detectable to 15.92 ng/mL. The authors support that penetration of tacrine into CSF is highly variable in patients with Alzheimer's disease and that disparity in tacrine concentrations at the site of action may be one reason for conflicting results from studies of the efficacy of tacrine in Alzheimer's disease." 10/29/1992 - "Of 632 eligible patients with probable Alzheimer's disease, 215 improved while receiving tacrine during a preliminary crossover phase to determine responsiveness and the best dose" 11/01/1999 - "OBJECTIVES: By reviewing the key methodological features (sample size, duration, statistical and clinical significance) of clinical trials examining the efficacy of tacrine in the treatment of Alzheimer's disease (AD), we assessed their ability to detect clinically important changes in cognition" 10/18/1988 - "Long-term administration of 9-amino-1,2,3,4-tetrahydroacridine (THA) has been reported to produce marked clinical improvement in patients suffering from Alzheimer's disease" 10/29/1992 - "In this short-term study in patients with Alzheimer's disease who were selected for apparent responsiveness to tacrine, treatment with tacrine resulted in a statistically significant reduction in the decline of cognitive function, although this reduction was not large enough to be detected by the study physicians' global assessments of the patients." Order ALL the reference details at left...
2.	Dementia (Dementias) 01/01/2007 - "The efficacy of tacrine for symptoms of dementia remains controversial" 01/01/2000 - "However, the efficacy of tacrine for symptoms of dementia remains controversial" 01/01/2007 - "SELECTION CRITERIA: All unconfounded, double-blind, randomized trials in which treatment with tacrine was administered for more than a day and compared to placebo in patients with dementia of the Alzheimer's type" 01/01/2007 - "The reasons for this are the small effects of tacrine compared to placebo for all outcomes; the high incidence of adverse events; the lack of benefit observed in several trials; the use of cross-over designs and their associated methodological problems in a disease like dementia; the use of different measurement scales to assess outcome in different trials; and the problem of high dropout rates" 01/01/2000 - "SELECTION CRITERIA: All unconfounded, double-blind, randomized trials in which treatment with tacrine was administered for more than a day and compared to placebo in patients with dementia of the Alzheimer's type" Order ALL the reference details at left...
3.	Memory Disorders (Memory Loss) 02/01/2000 - "The avoidance-memory deficit caused by Sco 0.05-5 mumol.kg-1 or Atr 5 mumol.kg-1 was completely or partly attenuated by tacrine, which did not antagonize the memory deficit elicited by Sco and Atr 50 mumol.kg-1, AT3 5 and 50 mumol.kg-1, and Ani 50 mumol.kg-1" 01/01/2000 - "INTRODUCTION: The anticholinesterase drug tacrine (Tac) is known to have a beneficial effect on memory deficit in mice involving in the process the cholinergic system in the brain" 12/01/1997 - "These results suggest that tacrine improvement of working memory deficit in the 2VO rats is due to stimulation of central cholinergic systems." 12/01/1997 - "Tacrine improves working memory deficit caused by permanent occlusion of bilateral common carotid arteries in rats." 02/26/1997 - "Systemic administration of tetrahydroaminoacridine at 1 or 3 mg/kg, i.p., ameliorated the memory deficits and EEG slowing induced by the basal forebrain lesion" Order ALL the reference details at left...
4.	Tremor (Tremors) 09/01/2004 - "Taken together, the results of this study indicate that A2A antagonists effectively reduce the magnitude of tremulous jaw movements induced in rats by acute tacrine, mainly by an action in VLS and suggest that A2A antagonists might be used as specific agents against parkinsonian tremor." 10/25/2006 - "Taken together, these results indicate that A(2A) antagonists reduce parkinsonian tremor stimulated in rats by tacrine and that the striatum is deeply involved in the observed effect" 07/01/2006 - "In order to better define the role of 5-HT(1A) receptors in the modulation of extrapyramidal motor functions, we investigated the effect of 5-HT(1A) agonists on tacrine-induced tremulous jaw movements (TJM) in rats, a putative model of parkinsonian tremor" 09/08/2005 - "These results indicate that the cholinergic tremor produced by tacrine in Balb/c mice is mediated via central serotonergic mechanisms, and stimulation of 5-HT(2A/2C) receptors plays a pivotal role in this motor dysfunction." 09/08/2005 - "Administration of tacrine (10-20 mg/kg, i.p.) produced dose- and time-dependent tremor in Balb/c mice" Order ALL the reference details at left...
5.	Amnesia (Dissociative Amnesia) 11/01/1991 - "Chronic tacrine (0.1-3 mg/kg, passive avoidance task, or 0.3 mg/kg, water maze task, once a day for 1 week) improved BF lesion-induced amnesia in the passive avoidance and water maze tasks" 09/01/1995 - "It is ten-fold more potent than tacrine in the amnesia-reversal assay and is considerably less toxic than tacrine." 04/22/1992 - "Tacrine (0.01-0.3 and 3 mg/kg), administered post-training, attenuated the acute amnesia but pre-retention test administration did not" 04/22/1992 - "In addition, NIK-247 (0.03, 0.1, 1 and 10 mg/kg) and tacrine (0.03, 0.1 and 1 mg/kg) administered before the retention test (7 days after CO exposure) improved retrieval in the delayed amnesia model" 11/01/1991 - "While cycloheximide (1.5 mg/kg, s.c.) produced amnesia in the passive avoidance task, chronic administration of tacrine (1, 3 and 10 mg/kg, once a day for 1 week) improved the amnesia" Order ALL the reference details at left...

Related Drugs and Biologics

1.	donepezil (Aricept)
2.	Acetylcholinesterase
3.	Cholinesterases (Cholinesterase)
4.	Physostigmine
5.	rivastigmine (Exelon)
6.	Cholinesterase Inhibitors (Anticholinesterases)
7.	amiridine (ipidacrine)
8.	huperzine A
9.	Tacrine (Cognex)
10.	Galantamine (Galanthamine)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Investigational Therapies (Experimental Therapy)
3.	Communication Aids for Disabled (TDD)
4.	Palliative Care (Palliative Medicine)
5.	Home Nursing (Nursing, Home)

Best Treatments:
Research Summary Report
on Alzheimer Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 948 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>